X-linked Retinoschisis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of X-linked retinoschisis (X-RS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of X-RS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets in this report.
Clarivate Epidemiology’s X-RS forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of X-RS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts two X-RS patient populations:
- Diagnosed prevalent cases of X-RS.
- Diagnosed prevalent cases of X-RS with the RS1+ mutation.
Note: Coverage may vary by country.
